S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Best Bear Market Funds: Top 3 Investment Options to Consider
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Best Bear Market Funds: Top 3 Investment Options to Consider
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Best Bear Market Funds: Top 3 Investment Options to Consider
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Best Bear Market Funds: Top 3 Investment Options to Consider
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
NASDAQ:IGMS

IGM Biosciences (IGMS) Stock Price, News & Analysis

$9.27
+0.59 (+6.80%)
(As of 03/27/2024 ET)
Today's Range
$8.65
$9.41
50-Day Range
$8.68
$17.36
52-Week Range
$3.81
$17.78
Volume
264,830 shs
Average Volume
258,460 shs
Market Capitalization
$544.98 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.80

IGM Biosciences MarketRank™ Stock Analysis

Analyst Rating
Hold
2.44 Rating Score
Upside/​Downside
92.0% Upside
$17.80 Price Target
Short Interest
Bearish
22.87% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.08
Upright™ Environmental Score
News Sentiment
0.49mentions of IGM Biosciences in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$80,927 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($3.23) to ($3.03) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.78 out of 5 stars

Medical Sector

258th out of 939 stocks

Pharmaceutical Preparations Industry

113th out of 435 stocks

IGMS stock logo

About IGM Biosciences Stock (NASDAQ:IGMS)

IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.

IGMS Stock Price History

IGMS Stock News Headlines

the most reliable asset on earth is making a comeback
Global tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.
IGMS Apr 2024 22.500 call
The AI Defense Stock Set to Soar
To protect our interests, The Pentagon has partnered with this small AI defense contractor - creating some of the most powerful AI defenses ever made.
RBC Capital upgrades IGM Biosciences to outperform
IGM Biosciences Inc Ordinary Shares IGMS
BofA gets more bearish on IGM Biosciences, downgrades shares
IGM Biosciences downgraded to Neutral from Buy at H.C. Wainwright
What To Know About HC Wainwright & Co.'s Downgrade of IGM Biosciences
See More Headlines
Receive IGMS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IGM Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/03/2023
Today
3/28/2024
Next Earnings (Estimated)
5/10/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:IGMS
Fax
N/A
Employees
224
Year Founded
2010

Price Target and Rating

Average Stock Price Target
$17.80
High Stock Price Target
$26.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+92.0%
Consensus Rating
Hold
Rating Score (0-4)
2.44
Research Coverage
9 Analysts

Profitability

Net Income
$-246,420,000.00
Net Margins
-11,568.83%
Pretax Margin
-11,537.00%

Debt

Sales & Book Value

Annual Sales
$2.13 million
Book Value
$3.46 per share

Miscellaneous

Free Float
25,331,000
Market Cap
$544.98 million
Optionable
Optionable
Beta
0.30

Social Links

13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Mr. Fred M. Schwarzer J.D. (Age 71)
    CEO, President & Director
    Comp: $977.66k
  • Dr. Bruce A. Keyt (Age 71)
    Chief Scientific Officer
    Comp: $692.95k
  • Dr. Chris H. Takimoto FACP (Age 65)
    M.D., Ph.D., Chief Medical Officer
    Comp: $684.95k
  • Mr. Misbah Tahir (Age 49)
    Chief Financial Officer
    Comp: $957.6k
  • Mr. TS Harigopal
    Senior Vice President of Group Operations
  • Mr. Steven Weber (Age 48)
    Senior VP, Corporate Controller & Principal Accounting Officer
  • Mr. Paul C. Graffagnino
    Vice President of Legal Affairs
  • Ms. Suzette Tauber (Age 60)
    Chief Human Resources Officer
  • Dr. Angus M. Sinclair Ph.D.
    Senior Vice President of Immuno-Oncology
  • Dr. Lisa L. Decker Ph.D. (Age 54)
    Chief Business Officer
    Comp: $528.18k

IGMS Stock Analysis - Frequently Asked Questions

Should I buy or sell IGM Biosciences stock right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for IGM Biosciences in the last year. There are currently 5 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" IGMS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IGMS, but not buy additional shares or sell existing shares.
View IGMS analyst ratings
or view top-rated stocks.

What is IGM Biosciences' stock price target for 2024?

9 brokerages have issued 1-year price targets for IGM Biosciences' stock. Their IGMS share price targets range from $7.00 to $26.00. On average, they anticipate the company's share price to reach $17.80 in the next year. This suggests a possible upside of 92.0% from the stock's current price.
View analysts price targets for IGMS
or view top-rated stocks among Wall Street analysts.

How have IGMS shares performed in 2024?

IGM Biosciences' stock was trading at $8.31 at the start of the year. Since then, IGMS shares have increased by 11.6% and is now trading at $9.27.
View the best growth stocks for 2024 here
.

Are investors shorting IGM Biosciences?

IGM Biosciences saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 4,760,000 shares, an increase of 5.5% from the February 29th total of 4,510,000 shares. Based on an average daily volume of 291,100 shares, the days-to-cover ratio is presently 16.4 days. Currently, 22.9% of the shares of the company are short sold.
View IGM Biosciences' Short Interest
.

When is IGM Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024.
View our IGMS earnings forecast
.

How were IGM Biosciences' earnings last quarter?

IGM Biosciences, Inc. (NASDAQ:IGMS) issued its quarterly earnings results on Thursday, August, 3rd. The company reported ($1.43) earnings per share for the quarter, missing the consensus estimate of ($1.40) by $0.03. The firm had revenue of $0.45 million for the quarter, compared to the consensus estimate of $0.80 million. IGM Biosciences had a negative net margin of 11,568.83% and a negative trailing twelve-month return on equity of 103.20%. The company's revenue for the quarter was up 22.4% compared to the same quarter last year. During the same period last year, the firm earned ($1.33) earnings per share.

What ETFs hold IGM Biosciences' stock?

ETFs with the largest weight of IGM Biosciences (NASDAQ:IGMS) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR).Virtus LifeSci Biotech Clinical Trials ETF (BBC).

What other stocks do shareholders of IGM Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IGM Biosciences investors own include Pfizer (PFE), Tesla (TSLA), AbbVie (ABBV), ImmunoGen (IMGN), Plug Power (PLUG), Atreca (BCEL), Carnival Co. & (CCL), Cisco Systems (CSCO), Dropbox (DBX) and Energy Transfer (ET).

When did IGM Biosciences IPO?

IGM Biosciences (IGMS) raised $125 million in an IPO on Wednesday, September 18th 2019. The company issued 7,800,000 shares at a price of $15.00-$17.00 per share. Jefferies, Piper Jaffray, Stifel and Guggenheim Securities served as the underwriters for the IPO.

Who are IGM Biosciences' major shareholders?

IGM Biosciences' stock is owned by many different retail and institutional investors. Top institutional shareholders include Price T Rowe Associates Inc. MD (5.58%), Price T Rowe Associates Inc. MD (5.58%), Goldman Sachs Group Inc. (1.78%), Goldman Sachs Group Inc. (1.78%), Vanguard Group Inc. (1.54%) and Vanguard Group Inc. (1.54%). Insiders that own company stock include Bros Advisors Lp Baker, Bruce Keyt, Chris H Takimoto, Daniel Shinyu Chen, Fred Schwarzer, George Gauthier, Jakob Haldor Topsoe, Julie Hambleton, M Kathleen Behrens, Michael D Loberg, Misbah Tahir and Steven Weber.
View institutional ownership trends
.

How do I buy shares of IGM Biosciences?

Shares of IGMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:IGMS) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners